FDA Drug recall D-0290-2017
Sermorelin Forte 6 mg (Sermorelin Acetate 6 mg/GHRP-6 3 mg)
- FDA Drug
- Class II
- ongoing
- Published 2017-01-11
On 2017-01-11 the FDA classified a Class II recall of Sermorelin Forte 6 mg (Sermorelin Acetate 6 mg/GHRP-6 3 mg) by Tri Coast Pharmacy, citing lack of Assurance of Sterility.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0290-2017 |
| Classification | Class II |
| Status | ongoing |
| Initiated | 2016-11-17 |
| Published | 2017-01-11 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Tri Coast Pharmacy |
| Distribution | US |
Product
Sermorelin Forte 6 mg (Sermorelin Acetate 6 mg/GHRP-6 3 mg). Compounded by Tri-Coast Pharmacy
Reason
Lack of Assurance of Sterility
Identifiers
| code_info | Recall includes all sterile products compounded between 05/17/2016 and 11/17/2016. Known lot codes (Exp Date): 10192016A (04/17/2017). |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0290-2017%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.